The above findings show that ERAP2 is a key gene affecting gemcitabine resistance in patients with pancreatic cancer, which enable us to further study whether there is a relationship between ERAP2 and the diagnosis and prognosis of pancreatic cancer. This evidence concerns the gene ERAP2 and familial pancreatic carcinoma.